Lucile Packard Children's Hospital Stanford Ranks Among Top Children's Hospitals by U.S. News & World Report and Ties for Best in Northern California

News provided by

Stanford Medicine Children's Health and Lucile Packard Children's Hospital Stanford

Sep 15, 2026, 00:01 ET

Nationally recognized in all pediatric specialties, with two specialties ranked in the top 5

Key rankings:

- Best Children's Hospital in Northern California

- Ranked No. 2 Children's Hospital in California

- Top 5 nationally in two specialties: Neonatology and Nephrology

- Top 10 nationally in four specialties: Neonatology, Nephrology, Neurology & Neurosurgery, and Pulmonology & Lung Surgery

PALO ALTO, Calif., Sept. 15, 2026 /PRNewswire/ -- Lucile Packard Children's Hospital Stanford was named among the nation's top pediatric medical centers, according to the U.S. News & World Report 2026–2027 Best Children's Hospitals survey. Packard Children's tied for the top ranking in Northern California and ranked No. 2 (tie) in the state.

For the 11th straight year, Packard Children's, the center of Stanford Medicine Children's Health, ranked nationally in all 11 pediatric specialties in the survey, underscoring the hospital's unwavering dedication to delivering highly specialized, multidisciplinary pediatric care.

Four of the hospital's specialties ranked in the top 10 nationwide:

- Neonatology (No. 4)

- Nephrology (No. 4)

- Neurology and Neurosurgery (No.7)

- Pulmonology and Lung Surgery (No. 8)

Additional pediatric specialties that earned national recognition were Cancer; Cardiology and Heart Surgery; Diabetes and Endocrinology; Gastroenterology and Gastrointestinal Surgery; Orthopedics; Urology; and Adolescent Behavioral Health.

"This marks the 22nd consecutive year we have been ranked among the nation's top children's hospitals, and we are deeply honored to be recognized," said Paul A. King, CEO of Stanford Medicine Children's Health and Lucile Packard Children's Hospital Stanford. "This achievement reflects the dedication of our physicians, nurses, and staff who provide their exceptional expertise and world-class care to every child and mother we serve. Through our nationally recognized specialty programs and groundbreaking research, we continue to advance pediatric medicine and improve outcomes for children and families everywhere."

Packard Children's also ranked No. 3 (tie) in the Pacific Region and is Best in the West for Neonatology and Nephrology. These distinctions reinforce the hospital's position as a leading destination for pediatric care and a trusted resource for families.

The U.S. News & World Report Best Children's Hospitals rankings are a comprehensive source of quality-related information on U.S. pediatric hospitals. They help families of children with rare or life-threatening illnesses find high-quality medical care available in consultation with their doctors and other medical professionals.

Media Contact

Michelle Macaluso

[email protected]

(650) 546-1363

About Stanford Medicine Children's Health

Stanford Medicine Children's Health, with Lucile Packard Children's Hospital Stanford at its center, is the Bay Area's largest healthcare system exclusively dedicated to children and expectant mothers. Our network of care includes more than 65 locations across Northern California and more than 85 locations in the U.S. Western region. Along with Stanford Health Care and the Stanford School of Medicine, we are part of Stanford Medicine, an ecosystem harnessing the potential of biomedicine through collaborative research, education, and clinical care to improve health outcomes around the world. We are a nonprofit organization committed to supporting the community through meaningful outreach programs and services and providing necessary medical care to families, regardless of their ability to pay. Discover more at stanfordchildrens.org.

SOURCE Stanford Medicine Children's Health and Lucile Packard Children's Hospital Stanford

Share this article

Discover the restaurants and experiences shaping the future of culinary travel with new experiential categories: Food Tours, Cooking Classes, Wine & Beer Tours, and the crowd-favorite Viral Right Now

NEEDHAM, Mass., Sept. 15, 2026 /PRNewswire/ -- Tripadvisor, the world's leading travel platform, today announced the winners of its annual Travelers' Choice Awards: Best of the Best Restaurants for 2026.

Based on first-hand reviews and opinions submitted by a global community of millions of diners over the last year, winners rank among the top one percent of all listings on Tripadvisor, offering a trusted guide to unforgettable meals for travelers across the globe.

Categories for this year's awards include Fine Dining, Casual, Date Night, Hidden Gems, and Vegan & Vegetarian, as well as four new categories centered on food experiences. As travelers increasingly seek out immersive culinary experiences that bring destinations to life, this year's awards introduce Best of the Best Food Tours, Cooking Classes, Wine & Beer Tours, and a Viral Right Now category highlighting current top trending culinary sensations.

"Food is at the heart of how we experience a destination, and these awards recognize the restaurant and culinary experiences travelers consider among the very best," said Laurel Greatrix, Chief Communications Officer, Tripadvisor Group. "From cooking classes with locals to incredible food tours and restaurants, these are the kinds of experiences that can become a highlight of a trip — or even a reason to take one."

This year's awards bring together acclaimed culinary icons and local institutions across Tripadvisor's core restaurant categories. Fogón Asado in Buenos Aires claims the No. 1 spot in the world on the Fine Dining list for its intimate, interactive open fire asado tasting experience, while Ristorante Paoletti in Highlands, North Carolina, grabs the top title in the U.S. for its elevated Northern Italian cuisine and legendary wine cellar.

In Casual Dining, Parisian crowd-favorite Pizzeria Arrivederci earns the highest global honors, while coastal gem Hook & Barrel in Myrtle Beach, South Carolina, ranks No. 1 in the U.S. (and No. 7 worldwide) for sustainable seafood and warm hospitality.

Expanding beyond traditional sit-down meals, this year's awards also spotlight the growing appetite for immersive, bookable culinary experiences and social-media-driven discoveries through four new experiential categories. Leading the global Food Tours list is the Reykjavik Food Walk in Iceland, offering travelers immersive tastings of local specialties, while Seattle's Chef Guided Food Tour of Pike Place Market secures the No. 1 spot in the U.S.

In Cooking Classes, the Rome Pasta and Tiramisu Class ranks No. 1 globally for turning travelers into authentic Italian home chefs, while the Cape Town Wine Tour (Paarl, Franschhoek & Stellenbosch) and Michigan's 5-Hour Traverse City Wine Tour claim top honors in Wine & Beer Tours for the World and U.S., respectively.

The new Viral Right Now list recognizes world-famous foodie sensations that have captured global social feeds, headlined by London's beloved Bombay-style eatery Dishoom and Ho Chi Minh City's legendary Banh Mi Huynh Hoa.

The 2026 Travelers' Choice Awards: Best of the Best Restaurants are part of Tripadvisor's larger Travelers' Choice Awards umbrella, recognizing travelers' favorite destinations and experiences around the world. The Travelers' Choice Best of the Best Awards are determined based on the quality and quantity of traveler reviews and ratings specific to each subcategory posted on Tripadvisor over a 12-month period, backed by an editorial review process that places winners among the top 1% of listings on the platform.

Best Fine Dining

Celebrating the world's most exceptional restaurants where culinary mastery and unforgettable experiences define every meal.

Top 10 Fine Dining Restaurants in the World

- Fogón Asado – Buenos Aires, Argentina

- KOMA Singapore – Singapore

- The Rhythms Restaurant – Hanoi, Vietnam

- The Witchery Restaurant – Edinburgh, United Kingdom

- Meat Market – Valencia, Spain

- Abrasado – Guaymallen, Argentina

- Catherine Gramado – Gramado, Brazil

- Careyes restaurant – Cancun, Mexico

- Acre – San Jose del Cabo, Mexico

- El Mercado – Buenos Aires, Argentina

See the full list of the Best of the Best Fine Dining Restaurants in the world here.

Top 10 Fine Dining Restaurants in the U.S.

- Ristorante Paoletti – Highlands, North Carolina

- Michael Anthony's Cucina Italiana – Hilton Head, South Carolina

- Bourbon Steak by Michael Mina – New York City, New York

- Bourbon Steak by Michael Mina, a Nashville Steakhouse – Nashville, Tennessee

- Primal Steakhouse – Las Vegas, Nevada

- Hakkasan Miami – Miami Beach, Florida

- Beach Walk at Henderson Park Inn – Destin, Florida

- Brenner's on the River Walk – San Antonio, Texas

- Vic & Anthony's Steakhouse – Lake Charles, Louisiana

- Swizzle Dinner & Drinks – Louisville, Kentucky

See the full list of the Best of the Best Fine Dining Restaurants in the U.S. here.

Best Hidden Gems

Celebrating the world's best-kept culinary secrets, where local flavor, authenticity and unexpected delights turn every meal into a discovery.

Top 10 Hidden Gems Restaurants in the World

- Tua Casa Hamburgueria E Petiscaria – Maragogi, Brazil

- Sad Man's Tongue Bar & Bistro – Prague, Czech Republic

- Hanoi-Oi Kitchen – Hanoi, Vietnam

- Sfiziarte – Rome, Italy

- Taberna Clandestina Cascais – Cascais, Portugal

- Shinjuku Sushi Hatsume – Tokyo, Japan

- Green Point – Cusco, Peru

- Archontiko – Agios Nikolaos, Greece

- Tierra Roja Restaurant – Chia, Colombia

- Kaleici Steak Gastro Bar – Antalya, Türkiye

See the full list of the Best of the Best Hidden Gems Restaurants in the world here.

Top 10 Hidden Gems Restaurants in the U.S.

- Casa Neos – Miami, Florida

- Caffe Milano – Naples, Florida

- Pickin Porch Grill – Branson, Missouri

- Local Goat - New American Restaurant – Pigeon Forge, Tennessee

- Riverfront Seafood Co – Kingsport, Tennessee

- Hosteria Romana – Miami Beach, Florida

- Big Daddy J's 5 Great Things – Cocoa Beach, Florida

- Gourmet Deli House – Lake Worth, Florida

- The Trophy Room at Old Kinderhook – Camdenton, Missouri

- The Travelin Lobster – Bar Harbor, Maine

See the full list of the Best of the Best Hidden Gems Restaurants in the U.S. here.

Best Culinary Experiences

Highlighting immersive food and drink experiences that let travelers taste a culture from the inside out.

Top 10 Food Tours in the World

- Reykjavik Food Walk - Local Foodie Adventure in Iceland – Reykjavik, Iceland

- Undiscovered Lisbon Food & Wine Tour by Eating Europe – Lisbon, Portugal

- Amsterdam Food and Cultural Tour with 10 Tastings – Amsterdam, The Netherlands

- From Split: Krka Waterfalls, Food & Wine Tasting Tour – Split, Croatia

- Rome Twilight Trastevere Food Tour by Eating Europe – Rome, Italy

- Hungry Osaka Street Food Tour: 15 Tastings & 3 Drinks with a Local – Osaka, Japan

- From Barcelona: Half-Day Montserrat, Tapas & Wine Tour – Barcelona, Spain

- Greek Food Walking Tour in Athens – Athens, Greece

- Devour Paris Ultimate Food Tour – Paris, France

- Lima Ultimate Peruvian Food Tour – Lima, Peru

Top 10 Food Tours in the U.S.

- Chef Guided Food Tour of Pike Place Market – Seattle, Washington

- New Orleans Food Walking Tour of the French Quarter (Small-Group) – New Orleans, Louisiana

- Charleston French Quarter or Brunch Food Tour with 7+ Tastings – Charleston, South Carolina

- Greenwich Village Food Tour | Tasty Tours NYC – New York City, New York

- Boston Sweet Treats Food Tour: Fresh Donuts, Cider & Much More – Boston, Massachusetts

- Nashville: Authentic Food Tour with 5 Tastings of Local Dishes – Nashville, Tennessee

- Chicago Favorites Ultimate Food and Walking Tour – Chicago, Illinois

- Taste of Little Italy in San Diego – San Diego, California

- Seattle's Sweetest Food Tour: Delicious Donuts, Beignets, & More – Seattle, Washington

- Las Vegas: The Strip's Celebrity Chefs Tour or Downtown Food Tour – Las Vegas, Nevada

Top 10 Viral Right Now in the World

- Dishoom – London, United Kingdom

- Banh Mi Huynh Hoa – Ho Chi Minh City, Vietnam

- Mad Hatter's Tea at Sanderson's – London, United Kingdom

- Tokyo Tsukiji Fish Market Food Walking Tour with 5 Tastings – Tokyo, Japan

- Turkey and the Wolf – New Orleans, Louisiana, United States

- Private Street Food Tour by Motorbike/Car with Local Students – Ho Chi Minh City, Vietnam

- Cremeria Santo Stefano – Bologna, Italy

- #1 Rated Lima Cooking Class: Make Ceviche, Causa & Pisco Sours! – Lima, Peru

- Istanbul Taste of Two Continents Food Tour - Spice Market & Ferry – Istanbul, Türkiye

- Karaköy Güllüoğlu – Istanbul, Türkiye

See all category winners and full global rankings on the Tripadvisor Travelers' Choice Awards portal.

More to Discover and Enjoy

Tripadvisor's 2026 Travelers' Choice Awards: Best of the Best Restaurants winners span a wide variety of tastes and activity levels, from standout dining destinations to immersive culinary experiences. For a full list of this year's winners, visit https://www.tripadvisor.com/TravelersChoice-Restaurants.

Methodology

The 2026 Best of the Best Restaurants are calculated based on the quality and quantity of reviews and ratings for restaurants on Tripadvisor collected over a 12-month period, July 1, 2025 through June 30, 2026, specific to each award subcategory, as well as an additional editorial process.

About Tripadvisor Inc.

Tripadvisor, the world's largest travel guidance platform*, helps millions of people each month** become better travelers, from planning to booking to taking a trip. Travelers across the globe use Tripadvisor's website and app to discover where to stay, what to do and where to eat based on guidance from those who have been there before.

As foundation models grow more capable, deploying them requires more power, memory bandwidth, and capital while adding infrastructure complexity. EUCLYD is developing a platform spanning crafted compute, innovative memory architecture, and datacenter systems to break this efficiency wall and transform AI inference economics.

EUCLYD's long-term vision is Abundant Intelligence: a future in which advanced AI is no longer constrained by infrastructure cost, power availability, or geography. Founded by Bernardo Kastrup and Atul Sinha at High Tech Campus Eindhoven, Europe's smartest square kilometer, EUCLYD draws on the campus's semiconductor ecosystem and Europe's engineering heritage.

At the center of EUCLYD's roadmap are craftwerk, the world's first agentic AI silicon, and craftwerk station CWS, the world's lowest-power exascale AI factory. The platform combines programmable ASIC compute, processor-memory co-design, and system-level optimization to overcome the memory and efficiency walls limiting AI performance and scalability.

"AI is becoming a foundation of economic growth, scientific discovery, and national competitiveness, but its potential will remain constrained unless we fundamentally change the infrastructure beneath it," said Bernardo Kastrup, Founder and Chief Executive Officer of EUCLYD. "This financing accelerates our mission to make intelligence abundant through greater efficiency, lower cost per token, and broader access to advanced AI."

"The next phase of AI will be defined not only by model innovation, but also by the efficiency and scalability of its infrastructure," said Dede Goldschmidt, Senior Vice President of Samsung Electronics and Head of the Samsung Semiconductor Innovation Center. "EUCLYD combines an accomplished team with a differentiated vision addressing constraints in AI datacenters."

"Europe has the engineering talent to produce globally significant technology companies," said Ted Persson, Partner at EQT and Co-Head of the Scaleup Europe Fund. "EUCLYD combines deep semiconductor expertise with a mission to tackle some of the hardest constraints in AI infrastructure. That mix of European engineering depth and global ambition is what we're here to back."

"Europe possesses world-class capabilities across semiconductors, advanced manufacturing, and systems engineering," said Peter Wennink, Chairman of the Board of EUCLYD and former President and Chief Executive Officer of ASML. "EUCLYD can transform those strengths into a globally competitive AI infrastructure platform."

The financing will expand EUCLYD's engineering organization, accelerate its silicon and systems roadmap, strengthen ecosystem partnerships, and prepare the company for commercial deployment across enterprise, sovereign, and hyperscale AI markets.

ABOUT EUCLYD

EUCLYD is a European semiconductor systems company developing ultra-efficient infrastructure for foundation AI models. Its roadmap spans agentic AI silicon, advanced memory architecture, and datacenter systems engineered to reduce cost, energy use, and footprint. EUCLYD is headquartered in Eindhoven, the Netherlands.

https://euclyd.ai/

MEDIA CONTACT

Catchfire

[email protected]

NOTES TO EDITORS

Investor Information

About the Scaleup Europe Fund, managed by EQT

The Scaleup Europe Fund, managed by EQT, is a commercially driven alternative investment fund backing ambitious European technology companies with the potential to become global leaders. Targeting €5 billion, the Fund brings together public and private capital and invests across Deeptech, AI and Life Sciences.

EQT is a global investment organization with a Nordic heritage and more than three decades of experience developing companies. With €341 billion in total assets under management, EQT invests across the full lifecycle of companies, from start-up to maturity.

About Somerset Capital Partners

Somerset Capital Partners was founded in 2005 by Joes Daemen and pursues a long-term, multi-asset investment strategy. We invest both directly and indirectly across a diverse range of sectors, including technology, real estate, strategic land, data centres, consumer, and healthcare.

We partner with ambitious entrepreneurs and founders, recognising that transformative ideas require capital, conviction, and time. Therefore, we are committed to fostering enduring and impactful long-term relationships.

About Innovation Industries

Innovation Industries is a leading European Deep tech venture capital firm with €1 billion in capital under management. The firm invests in visionary science and engineering-based companies that tackle the world's most pressing challenges. With a strong belief that Deep tech can deliver both outsized financial returns and global impact, Innovation Industries partners with exceptional entrepreneurs and researchers to turn scientific breakthroughs into transformative companies. The firm provides long-term capital and strategic support from lab to scale, actively bridging the gap between academia and industry through close collaboration with leading technical universities, research institutions and industry partners. Innovation Industries has offices in Amsterdam, Eindhoven and Munich.

About EIFO 

As Denmark's national promotional bank and official export credit agency, EIFO works to open doors for global business, drive the green transition, advance innovative technologies, and contribute to Denmark's security.

With total commitments exceeding EUR 24 billion and activities in more than 100 countries, EIFO provides financial solutions to Danish companies and their global partners.

EIFO is also Denmark's most active venture investor, investing in startups and VC-funds. In 2025, EIFO made 31 new investments in companies and 15 in funds. Altogether, EIFO has an investment portfolio of just over EUR 2,7 billion.

About imec.xpand

imec.xpand is one of the world's largest independent venture capital funds dedicated to early-stage semiconductor innovation. It targets ambitious startups where the knowledge, expertise and infrastructure of imec, the world-renowned semiconductor and nanotechnology R&D center, can play a determining role in their growth. imec.xpand has an outspoken international mindset towards building disruptive global companies and strongly believes that sufficient funding from the start is key to future success.

About Brabant Development Agency

Entrepreneurship is the driver of innovation – from sustainable food sources to a healthy future, climate-neutral energy, and developing promising key technologies. The Brabant Development Agency (BOM) ensures that startups playing a role in these fields receive the right support and funding to get off to a solid start and grow into scaleups, and that companies that aspire to go global can actually do so. BOM is an executive body of the Province of Brabant and the Ministry of Economic Affairs and Climate.

About Quadri

Quadri is a venture capital firm investing in category-defining companies across Enterprise AI, Physical AI, and AI Infrastructure. With offices in London and New York, we leverage our global enterprise network to accelerate commercial adoption and international expansion. For more information, visit quadri.vc.

Share this article

Collaboration will bring the needs of underserved communities into the open ecosystem shaping agentic AI

Summary

- Gates Foundation becomes the first philanthropic organization to join the Agentic AI Foundation (AAIF) and bring its global perspective across health, education, agriculture and economic opportunity to the open source and open standards ecosystem shaping agentic AI.

- Collaboration will help ensure the needs of underserved communities and low-income countries are considered as the foundational technologies and standards for agentic AI are developed.

- Gates Foundation will serve as a Diamond Sponsor of the first Africa-based MCP Dev Summit in Nairobi, supporting attendees from across the continent to join and drawing on its network of partners and grantees to help ensure broad representation across African countries and communities at the event.

SAN FRANCISCO, Sept. 15, 2026 /PRNewswire/ -- The Agentic AI Foundation (AAIF), the neutral home where the agentic stack is being built, today announced that the Gates Foundation has joined as the first philanthropic organization, with Matt Vasey, senior advisor of AI strategy and ecosystems, taking a seat on the AAIF board. The Gates Foundation brings its perspective across global health, education, agriculture and economic opportunity to the community building the open technologies and standards that will underpin agentic AI.

"AI has enormous potential to expand opportunity, but realizing that potential requires being deliberate about who has a voice in shaping the technology," said Mazin Gilbert, executive director of the Agentic AI Foundation. "Too often, the communities that stand to benefit the most from a new technology are far removed from the places where the underlying decisions are made. The Gates Foundation brings that perspective into AAIF and by connecting developers and communities around the world with the open projects building the foundations of agentic AI, we can widen the circle of people shaping what comes next."

The Gates Foundation has long worked to ensure advances in technology translate into meaningful progress for people around the world, particularly in underserved communities. As AI creates new possibilities across health, education, agriculture, and economic opportunity, the foundation is focused on helping ensure those benefits are broadly shared. Its membership in AAIF extends that work to the foundational layer of agentic AI, bringing perspectives from the communities it serves into an open, neutral forum, and actively contributing to the technical direction of AAIF's open projects and standards, both current and future, so that LMIC needs are reflected at the foundational layer of the ecosystem.

Together, AAIF and the Gates Foundation will work to broaden participation in the open source communities building agentic AI, including by creating more opportunities for developers in regions that have historically been underrepresented in major technology ecosystems to participate and contribute.

That commitment will begin with MCP Dev Summit Nairobi, where the Gates Foundation has established a fund to support attendance innovators across the continent. The investment will help more developers access the region, connect with the broader community and participate directly in conversations around the open technologies shaping agentic AI. To learn more about MCP Dev Summit Nairobi, click here.

"The standards being developed today will determine whether AI actually works for the billions of people the Gates Foundation aims to serve in underserved communities and low-income countries," said Matt Vasey, senior advisor at the Gates Foundation. "We're joining AAIF because getting this right requires building with equity from the start so this technology can truly transform lives and livelihoods everywhere."

By joining the AAIF, new members gain access to a global ecosystem where they can directly shape emerging standards, collaborate on open source innovation, and help meet growing demand for interoperable, standardized agentic infrastructure. For information on becoming a member, visit our website.

About the Agentic AI Foundation

The Agentic AI Foundation (AAIF) is the neutral home where the agentic stack is being built. With founding projects including MCP, A2A, AGENTS.md, goose, agentgateway, and Agent Router, AAIF governs the core standards and protocols that enable agents to operate interoperably across platforms. Through transparent governance and broad industry participation, AAIF is driving adoption and ensuring agentic AI infrastructure evolves openly, predictably, and at production scale. For more information, please visit aaif.io.

Media Contact

Sarah Zonouzi

Agentic AI Foundation

[email protected]

SOURCE Agentic AI Foundation

Share this article

Texas Children's Named a Best Children's Hospital and is Number One in Texas Again for 18th Consecutive Year

Heart Center ranked Number One in the nation for 10th consecutive year; Diabetes & Endocrinology also earned country's top ranking

HOUSTON, Sept. 15, 2026 /PRNewswire/ -- Texas Children's has again been named to the U.S. News & World Report Best Children's Hospitals Honor Roll. The hospital remains No. 1 in Texas for the 18th consecutive year and No. 1 in the Southwest for the sixth consecutive year, with every evaluated specialty recognized nationally.

Texas Children's Heart Center ranks No. 1 in Pediatric Cardiology & Heart Surgery for the 10th consecutive year, extending a decade of national leadership. Texas Children's also earned the No. 1 ranking in Pediatric Diabetes & Endocrinology.

"For families facing the most complex or common diagnoses, these rankings represent something deeply personal: confidence that their child can receive extraordinary care from teams who are committed to clinical excellence and solving the unsolvable," said Dr. Debra Sukin, President and CEO of Texas Children's. "Earning the nation's No. 1 ranking in heart care for a full decade, reaching No. 1 in diabetes and endocrinology and once again leading Texas and the Southwest reflects the skill, compassion and relentless commitment of our physicians, nurses, researchers and staff. I am incredibly proud of what this team accomplishes together for children and families here at home and around the world."

Nine specialties ranked among the nation's top five, including five in the top two. Pediatric & Adolescent Behavioral Health also received a Top 50 designation.

All specialties are ranked nationally

With the partnership of academic affiliate Baylor College of Medicine, Texas Children's - the largest freestanding children's hospital in the country - is a distinguished leader and resource for children and their families. The hospital earns U.S. News Honor Roll distinction by ranking:

- No. 1: Cardiology & Heart Surgery

- No. 1: Diabetes & Endocrinology

- No. 2: Nephrology (Kidney disorders)

- No. 2: Pulmonology & Lung Surgery

- No. 2: Urology

- No. 3: Neurology & Neurosurgery

- No. 5: Gastroenterology & GI Surgery

- No. 5: Neonatology

- No. 5: Orthopedics

- No. 12: Cancer

- Top 50: Behavioral Health

"As clinicians, we see every day what it means for a family to have highly specialized teams working together around their child," said Dr. Larry Hollier, President of Health Affairs at Texas Children's and Vice Chair of Surgery at Baylor College of Medicine. "Having every evaluated specialty recognized nationally reflects the depth of clinical expertise, research and innovation across Texas Children's. It also speaks to the collaboration among our physicians, nurses, and the many other clinical professionals who bring their expertise to patients with the most complex needs. This recognition is a testament to their shared commitment to advancing medicine and leading the way in caring for women, children and families."

Global leader in pediatric heart care: Texas Children's Heart Center remains best in the nation

For more than 60 years, Texas Children's Heart Center® has combined advanced technology with compassionate, family-centered care. Its multidisciplinary teams perform more than 1,000 surgeries and 1,600 cardiac catheterization procedures annually, caring for patients with some of the rarest and most complex heart conditions. The program's 10th consecutive No. 1 ranking reflects sustained excellence from diagnosis through treatment and lifelong follow-up.

National leader in pediatric diabetes and endocrinology

Texas Children's Diabetes & Endocrinology program provides multidisciplinary care for children with diabetes and a wide range of complex endocrine disorders. Across its clinic locations, the program uses standardized, evidence-based care, a same-day sick clinic, advanced technologies such as insulin pumps and continuous glucose monitors, and real-time clinical alerts to expand access, improve outcomes and help ensure patients receive recommended services and screenings.

U.S. News & World Report ranking methodology

U.S. News & World Report introduced the Best Children's Hospitals rankings to help families of children with rare or life-threatening illnesses find the best medical care available. The rankings consider clinical outcomes and resources, patient safety, infection prevention, nurse staffing and other measures, along with input from pediatric specialists.

About Texas Children's

Texas Children's, a nonprofit health care organization, is committed to creating a healthier future for children and women throughout the global community by leading in patient care, education and research. Consistently ranked as the best children's hospital in Texas and among the top in the nation, Texas Children's has garnered widespread recognition for its expertise and breakthroughs in pediatric and women's health. The system includes the Texas Children's Duncan NRI; the Feigin Tower for pediatric research; Texas Children's Pavilion for Women, a comprehensive obstetrics/gynecology facility focusing on high-risk births; Texas Children's Hospital West Campus, a community hospital in suburban West Houston; Texas Children's Hospital The Woodlands, the first hospital devoted to children's care for communities north of Houston and Texas Children's Hospital North Austin, the state-of-the-art facility providing world-class pediatric and maternal care to Austin families. The organization also created Texas Children's Health Plan, the nation's first HMO focused on children; Texas Children's Pediatrics, the largest pediatric primary care network in the country; Texas Children's Urgent Care clinics that specialize in after-hours care tailored specifically for children; and a global health program that is channeling care to children and women all over the world. Texas Children's Hospital is affiliated with Baylor College of Medicine. For more information, visit www.texaschildrens.org.

Media Contact:

Texas Children's Public Affairs

[email protected]

SOURCE Texas Children's Hospital

Share this article

New solutions and innovations from VTT and Finnish food companies pave the way for profitable plant-based ingredient business

ESPOO, Finland, Sept. 15, 2026 /PRNewswire/ -- In recent years, the development of plant-based food ingredients has focused on proteins and their production processes. The RETHINK project by VTT and the Finnish food industry shows that achieving profitability in the sector requires a new way of thinking: value should be created from every stream generated in plant ingredient production, new ingredients need to be developed to suit their targeted end use, and companies and other operators must strive for closer cooperation. The project also produced several tangible inventions.

One of the key development goals for food system operators is a sustainable shift toward more plant-based diets. This shift will yield positive effects on public health, the environment and resilience of the society.

In the RETHINK project, funded by Business Finland, VTT Technical Research Centre of Finland and Finnish ingredient and food companies examined how profitable business can be built around the production of plant-based ingredients in the Finnish operating environment.

Plant-based ingredient production refers to the processing of plant raw materials, such as oats and faba beans, into various ingredients used by food manufacturers in food production.

"Globally, food production is shifting towards more local and distributed production models, as companies and societies strive to strengthen their resilience. Finland is in a great position to create new plant-based production chains and profitable business, leading to growth in the industry. We have plenty of active farmers and capacity for regional raw material production, as well as growing interest in plant-based products from the food industry and retail sector," says Emilia Nordlund, responsible leader of the project at VTT.

Complete raw material utilisation and closer collaboration will lead to profitability

Many current business models focus on plant protein production, which means a significant share of the raw material value is not maximally used. For example, peas yield protein for meat substitutes, but their carbohydrate-rich side streams often end up as animal feed with a considerably lower economic value than that of protein products. According to the experts working in RETHINK, profitable production models require creating added value from every fraction generated in ingredient production.

"It is especially critical to find the high value use cases for carbohydrate-rich fractions, as they often comprise the largest share of the raw material. We should be boldly looking for uses beyond the food sector too. In cosmetics, for example," Nordlund notes.

According to the project's experts, growth also requires closer collaboration among food system operators. Farmers, ingredient producers, food companies, investors and decision-makers need to build shared practices that reduce supply risks and enable production to scale. Investment-ready production models enable planning for raw material availability, quality, processing, end-use applications, and commercial routes as a unified whole.

One example of cross-company collaboration in the RETHINK project is the shared development work by Viking Malt and Valio, which produced a solution made from germinated faba bean protein granule for the plant-based and hybrid meat product market.

"Our collaboration is based on a shared goal: to maximise the value of Finnish plant-based raw materials by drawing on Finnish expertise and our best practices. Viking Malt's experience with germination and Valio's commercialisation know-how made it possible to create an entirely new kind of food product," say Susanna Kallio, Vice President, Plant-Based Business at Valio, and Xin Huang, Group R&D Manager at Viking Malt.

New inventions enable more effective use of grain and legume proteins and fibre

The new solutions developed by VTT during the project are geared towards securing locally profitable production as well as manufacturing nutritionally valuable ingredients and end products without complex processing. For example, enzyme-assisted processing methods reduce chemical use and improve the functionality of ingredients.

"In RETHINK, we patented an entirely new way to concentrate and apply oat dietary fibre, beta-glucan. This invention makes it possible to add fibre to liquid products so that the fibre stays intact while the liquid remains pourable and without a paste-like texture," Nordlund describes.

VTT researchers also developed a new pretreatment technique for the protein separation process, which prevents the unpleasant off-flavours typical of legume-based ingredients and expands the possibilities for using legumes in food products.

New spin-off company Happy Plant Protein upscales plant protein production

Research carried out under RETHINK also helped advance the technology commercialised by VTT spin-off Happy Plant Protein from the development stage toward commercial readiness. The new technology separates protein from carbohydrates and texturises the protein using only a single process step.

"Happy Plant Protein is reshaping the market with its production process. It's also an excellent example of a company with international ambitions making use of existing food industry infrastructure and local raw materials," Nordlund says.

The company has progressed from research innovation to international commercialisation, and its technology is now being used in industrial production projects in both Latvia and the Netherlands.

Project facts

- Public 3-year co-innovation project with 5 parallel projects from the Finnish food industry

- Duration: June 2023 to August 2026

- Funded by Business Finland, totaling €3 million

- Research partner: VTT (responsible leader of the project: Emilia Nordlund)

- Industrial partners: Anora, Apetit, Fazer, Helsingin Mylly, Raisio, Valio, Viking Malt

For more information

Emilia Nordlund, Portfolio Lead, VTT

[email protected], +358 40 504 2963

VTT White paper: How to build investable plant-based ingredient businesses

Further information on VTT:

Satu Holm-Jumppanen

Manager, Communications

+358 50 305 4718, [email protected]

www.vtt.fi

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

SOURCE VTT Info

Share this article

Seattle Children's ranks No. 1 in Washington state and ties for No. 1 in the Pacific region in latest U.S. News & World Report

SEATTLE, Sept. 15, 2026 /PRNewswire/ -- For the third year in a row, Seattle Children's has achieved the U.S. News & World Report's Best Children's Hospitals Honor Roll, a distinction awarded to only 10 children's hospitals across the country.

Seattle Children's was named the No. 1 pediatric hospital in Washington state and ranked No. 1 in the Pacific region in a tie. The Pacific region includes Alaska, California, Hawaii, Oregon and Washington.

The rankings help parents and caregivers, along with their physicians, navigate the challenges of choosing the best possible care for children with serious illnesses or complex medical needs. The rankings also reflect an organization's dedication to clinical outcomes, quality improvement and patient safety.

"Earning a spot among the nation's top 10 children's hospitals for the third consecutive year is a testament to every team member who shows up daily with purpose and dedication," said Seattle Children's CEO Dr. Christopher A. Longhurst. "It takes our entire team working together to guide caregivers through complex medical decisions and deliver world-class care, confirming our commitment to our mission of hope, care and cures."

Seattle Children's ranked in every specialty evaluated, with four specialties placing in the nation's top 10:

- Cancer

- Diabetes & Endocrinology

- Nephrology

- Pulmonology & Lung Surgery

For the 2026-2027 rankings, U.S. News, together with RTI International, a North Carolina-based research firm, collected and analyzed data from 114 children's hospitals and surveyed thousands of pediatric specialists. Children's hospitals awarded a "Best" designation excelled at factors such as clinical outcomes, compliance with established best practices and level and quality of hospital resources directly related to patient care.

The full rankings for the 2026-2027 Best Children's Hospitals Honor Roll, regional and specialty rankings can be found at USNews.com.

About U.S. News & World Report 

U.S. News & World Report is the global leader for journalism that empowers consumers, citizens, business leaders and policy officials to make confident decisions in all aspects of their lives and communities. A multifaceted media company, U.S. News provides unbiased rankings, independent reporting and analysis, and consumer advice to millions of people on USNews.com each month. A pillar in Washington for more than 90 years, U.S. News is the trusted home for in-depth and exclusive insights on education, health, politics, the economy, insurance, personal finance, travel, automobiles, real estate, careers and consumer products and services.    

About Seattle Children's

Seattle Children's mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children's Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.

Ranked as one of the top children's hospitals in the country by U.S. News & World Report, Seattle Children's serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest geographic region of any children's hospital in the country. As one of the nation's top pediatric research centers, Seattle Children's Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children's Foundation, along with Seattle Children's Guild Association – the largest all-volunteer fundraising network for any hospital in the country – works with our generous community to raise funds for lifesaving care and research.

For more information, visit seattlechildrens.org; follow us on X, Facebook, LinkedIn and Instagram; or subscribe to our Healthy Tides newsletter.

Media contact: [email protected]

SOURCE Seattle Children's

Share this article

Electronic Line Calling and AI Broadcasting Make CIFTIS Debut: Orange Lion Sports' Smartshot 2.0 Presents an Inclusive "Sports + AI" Solution

BEIJING, Sept. 15, 2026 /PRNewswire/ -- Orange Lion Sports, founded by Alibaba Group, has unveiled Smartshot 2.0, the upgraded version of its AI sports solution, at the Sports Services exhibition during the 2026 China International Fair for Trade in Services (CIFTIS), held September 9-13 in Beijing.

From six-camera Hawk-Eye electronic line calling and AI-powered auto-directing to the debut of a voice-interactive smart ball machine, the company is advancing a cost-effective approach to inclusive sports technology, bridging the gap between professional competition and mass participation to "make sports simple."

At CIFTIS 2026, Orange Lion Sports' replica tennis court became a focal point. Smartshot 2.0 introduced an upgraded electronic line calling system designed to address long-standing disputes over line calls at amateur tennis events. As soon as the ball lands, a large screen provides instant in/out calls and can announce "IN/OUT" at adjustable volumes. The system supports smoother, fairer amateur competitions at a low marginal cost without requiring additional labor.

AI commentary and auto-directing cut broadcasting costs of up to hundreds of thousands of yuan, making high-quality broadcasts more accessible. AI-powered robots are becoming a valuable complement to traditional sports coaching.

In Orange Lion Sports' roadmap, Smartshot will work with the smart ball machine to interact with trainees through natural language, instantly adjusting ball settings, placement and speed to create personalized training programs and help beginners improve more efficiently.

Leveraging Alibaba's technology capabilities, Smartshot has integrated the Tongyi Qwen large language model to launch what it describes as the industry's first "AI Tournament Assistant" in the first half of 2026. The assistant understands natural-language instructions and parses PDF regulations, enabling scheduling and registration to be completed in minutes. Smartshot now offers pricing at one-tenth that of comparable offerings.

"Our goal is to find the optimal balance between precision and cost control, consistent with our long-standing technical philosophy. We reject expensive professional premiums and pursue cost-effective, inclusive technology," said Peng Wei, CTO of Orange Lion Sports.

Since its launch, Smartshot has been deployed across more than 500 courts and expanded into overseas markets, with installations in Europe, Australia, Hong Kong SAR, and Taiwan region. Looking ahead, as AI advances in sports, Orange Lion Sports' approach to balancing commercial value with accessibility aims to make professional-grade smart equipment more affordable and accessible worldwide.

Share this article

- Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis

- Fewer than 1% of patients discontinued treatment due to treatment-related events at one year

- New findings from Johnson & Johnson build on the MARIPOSA survival benefit and strengthen evidence for RYBREVANT FASPRO plus LAZCLUZE as first-line treatment

SEOUL, South Korea, Sept. 14, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 2b COPERNICUS study evaluating how subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib), with less frequent dosing and prophylactic strategies, can improve the treatment experience for patients with previously untreated advanced non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations. Early results show consistently low rates across key treatment-related events and treatment discontinuation.1

COPERNICUS was designed to reflect everyday clinical practice, enrolling a racially and ethnically diverse patient population across both academic and community sites. The data were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) (Abstract #M012.09).1

RYBREVANT FASPRO dual-targets EGFR and mesenchymal-epithelial transition (MET), two key drivers of tumor growth and treatment resistance, while also engaging the immune system.2,3,4,5 It is approved across multiple EGFR-mutated advanced NSCLC treatment settings and, for eligible patients, offers once-monthly dosing following initial weekly dosing.6

Advancing the treatment experience with RYBREVANT-based regimens

"RYBREVANT plus LAZCLUZE has already shown that patients with EGFR-mutated lung cancer can live longer, and these latest results mark an important evolution in the treatment approach," said Balazs Halmos, M.D., M.S., Director of Thoracic Oncology and Associate Director of Clinical Science, Montefiore Einstein Comprehensive Cancer Center. "With subcutaneous administration, less frequent dosing and prophylactic strategies, the regimen has been developed with the treatment experience in mind, helping patients start treatment and stay on it."

"Our work with RYBREVANT in EGFR-mutated lung cancer has continued to evolve with each new piece of evidence, from extending survival to advancing how treatment is delivered and managed," said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. "COPERNICUS brings those learnings together in a study designed around the realities of clinical care. It reflects our commitment to continually innovate across the treatment journey so that scientific advances can make a meaningful difference for more patients."

Detailed study results

In this analysis, 214 U.S. patients received the recently approved RYBREVANT FASPRO plus LAZCLUZE regimen with prophylactic strategies to reduce the risk of blood clots with oral anticoagulation and skin-related side effects with an enhanced, easy-to-use skin care regimen evaluated in the COCOON study.1,7

At a median follow-up of 8.3 months, the majority of adverse events were Grade 1 or 2, with no new safety signals observed. Only eight percent of patients discontinued treatment due to adverse events. Rash was reported in 25 percent of patients, while administration-related reactions (ARRs) and venous thromboembolism (VTE) were each reported in three percent. No patients discontinued due to ARRs, and one percent discontinued due to rash and VTE.1

These findings represent lower numerical rates than observed with intravenous RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE in the Phase 3 MARIPOSA study, where rash, ARRs and VTE during the first four months of treatment were reported in 55 percent, 55 percent and 23 percent of patients, respectively. MARIPOSA also demonstrated that patients with advanced EGFR-mutated advanced NSCLC treated with the first-line regimen lived longer than those treated with osimertinib, with a statistically significant overall survival benefit (hazard ratio [HR], 0.75; P=0.005).8

COPERNICUS is one of the largest global studies conducted in patients with EGFR-mutated NSCLC, with a target enrollment of 300 previously untreated patients. Of the population reported here, median age was 67 years, 22 percent were age 75 or older, 27 percent were Asian, 10 percent were African American and 10 percent were Hispanic/Latino.1

This study reflects Johnson & Johnson's continued focus on improving the treatment experience for people with cancer, including how treatments are delivered and managed in everyday care.

About the COPERNICUS study

COPERNICUS (NCT06667076) is a Phase 2b, single-arm study evaluating RYBREVANT FASPRO plus LAZCLUZE with prophylactic strategies in patients with EGFR-mutated advanced non-small cell lung cancer. Cohort 1 evaluates the regimen in the first-line setting, incorporating once-every-four-weeks dosing, venous thromboembolism (VTE) and enhanced dermatologic prophylaxis.

The study uses a pragmatic design to more closely reflect real-world clinical practice, with participation from academic and community sites and reduced visit frequency. The primary endpoint is investigator-assessed progression-free survival per RECIST v1.1. Secondary endpoints include safety and tolerability measures, including VTE and dermatologic adverse events and administration-related reactions, as well as overall survival and overall response rate.9

About non-small cell lung cancer

Worldwide, lung cancer is one of the most common cancers, with non-small cell lung cancer (NSCLC) making up 80 to 85 percent of all lung cancer cases.10,11 The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.12 Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.13 EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.10,11,14,15,16,17 EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.18 The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent.19,20 EGFR exon 20 insertion mutations are the third-most prevalent activating EGFR mutation.21 Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.22

About RYBREVANT FASPRO and RYBREVANT

RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) received U.S. FDA approval in December 2025 and is approved in multiple markets worldwide for the treatment of adults with EGFR-mutated non-small cell lung cancer (NSCLC), including those with exon 19 deletions, exon 21 L858R substitution mutations, and exon 20 insertion mutations. It is the only subcutaneous therapy approved for these EGFR-mutated NSCLC populations and may be used as monotherapy or in combination with LAZCLUZE (lazertinib) or chemotherapy, depending on the specific mutation and treatment setting. For eligible patients, RYBREVANT FASPRO offers a once-monthly dosing option following initial weekly dosing. RYBREVANT FASPRO is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology.

RYBREVANT FASPRO is approved in the U.S. for the same indications as intravenous RYBREVANT (amivantamab-vmjw) across multiple markets. RYBREVANT is a first-in-class, fully human bispecific antibody targeting EGFR and MET, designed to inhibit tumor growth while engaging the immune system.

The effectiveness of RYBREVANT FASPRO is supported by the established clinical profile of RYBREVANT, including data from multiple Phase 3 studies such as MARIPOSA, which demonstrated improvements in progression-free and overall survival when used in combination with LAZCLUZE® in first-line advanced EGFR-mutated NSCLC.

The National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®)‡ 23 include amivantamab-vmjw (RYBREVANT) across its FDA-approved treatment settings, including as a Category 1 preferred option in combination with lazertinib (LAZCLUZE) for first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations. Subcutaneous amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO) may be substituted for IV amivantamab-vmjw (RYBREVANT) where appropriate. See the latest NCCN Guidelines® for NSCLC for complete information.§ ||

The NCCN Guidelines for Central Nervous System Cancers also include amivantamab (RYBREVANT)-based regimens, including in combination with lazertinib (LAZCLUZE), as the only NCCN-preferred combination options for patients with EGFR-mutated NSCLC and brain metastases.§ ||

Beyond NSCLC, RYBREVANT-based therapies are being investigated across other solid tumors, including head and neck and colorectal cancers.

The legal manufacturer for RYBREVANT FASPRO and RYBREVANT is Janssen Biotech, Inc. For more information, visit www.rybrevanthcp.com.

INDICATIONS

RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) and RYBREVANT (amivantamab-vmjw) are indicated:

- in combination with LAZCLUZE (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.

PARSIPPANY-TROY HILLS, N.J., Sept. 14, 2026 /PRNewswire/ -- PBF Energy Inc. (NYSE:PBF) ("PBF Energy") today announced that its indirect subsidiary, PBF Holding Company LLC ("PBF Holding"), priced $500 million in aggregate principal amount of 0% exchangeable notes due 2032 (the "Notes") in a private offering exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"). The offering is expected to close on September 17, 2026, subject to customary closing conditions. The Notes will be co-issued by PBF Finance Corporation, a wholly owned subsidiary of PBF Holding (together with PBF Holding, the "Issuers"). The Issuers also granted the initial purchasers of the Notes an option to purchase, for settlement within a period of 13 days from, and including, the date the Notes are first issued, up to an additional $50 million aggregate principal amount of Notes.

The Notes will be senior, unsecured obligations of the Issuers. The Notes will not bear regular interest and the principal amount of the Notes will not accrete. The Notes will be fully and unconditionally guaranteed, on a senior unsecured basis, by certain of PBF Holding's subsidiaries (the "Guarantors") that guarantee PBF Holding's existing senior unsecured notes, and will not be guaranteed by PBF Energy Inc. The Notes will mature on January 15, 2032, unless earlier repurchased, exchanged or redeemed. Noteholders will have the right to exchange their Notes in certain circumstances and during specified periods. Exchanges will be settled in cash up to the aggregate principal amount of the Notes to be exchanged and, if applicable, cash, Class A common stock, par value $0.001 per share ("Common Stock") of PBF Energy or a combination thereof, at the Issuers' election, in respect of the remainder (if any) of the Issuers' exchange obligations in excess of the aggregate principal amount of the Notes being exchanged.

The Issuers may not redeem the Notes prior to January 20, 2030, except in the event of a cleanup redemption (as defined below). The Notes will be redeemable, in whole or in part (subject to certain limitations), for cash at the Issuers' option at any time, and from time to time, on or after January 20, 2030 and prior to the 31st scheduled trading day immediately preceding the maturity date of the Notes, but only if the last reported sale price per share of Common Stock has been at least 130% of the exchange price of the Notes for a specified period of time and certain other conditions are satisfied. The redemption price will be equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid special interest, if any, to, but excluding, the redemption date. The Issuers may also redeem for cash all, but not less than all, of the Notes at any time prior to the 31st scheduled trading day immediately preceding the maturity date, if the principal amount of Notes outstanding at such time is less than 10% of the aggregate principal amount of the Notes initially issued under the indenture (including any additional Notes issued pursuant to the initial purchasers' option) (a "cleanup redemption").

If a "fundamental change" (as defined in the indenture for the Notes) occurs, then, subject to limited exceptions, noteholders may require the Issuers to repurchase their Notes for cash. The repurchase price will be equal to the principal amount of the Notes to be repurchased, plus accrued and unpaid special interest, if any, to, but excluding, the applicable repurchase date.

The initial exchange rate is 10.3306 shares of Common Stock per $1,000 principal amount of Notes, which represents an initial exchange price of approximately $96.80 per share of Common Stock. The initial exchange price represents a premium of approximately 37.5% above the last reported sale price per share of Common Stock on the New York Stock Exchange on September 14, 2026, which was $70.40 per share. The exchange rate and exchange price will be subject to adjustment upon the occurrence of certain events.

The holders of the Notes will be entitled to the benefits of a registration rights agreement pursuant to which the Issuers and PBF Energy have agreed to register the resale of the shares of Common Stock, if any, deliverable upon exchange of the Notes under the Securities Act. The registration rights agreement contains significant limitations, and a resale registration statement may not be available at the time investors wish to resell the shares of PBF Energy's Common Stock, if any, deliverable upon exchange of their Notes.

In connection with the pricing of the Notes, the Issuers and PBF Energy have entered into privately negotiated capped call transactions with one or more of the initial purchasers of the Notes or their respective affiliates or certain other financial institutions (the "option counterparties"). The capped call transactions cover, subject to anti-dilution adjustments substantially similar to those applicable to the Notes, the number of shares of Common Stock initially underlying the Notes. The capped call transactions are expected generally to reduce the potential dilution to PBF Energy's Common Stock upon any exchange of Notes and/or offset any cash payments the Issuers are required to make in excess of the principal amount of exchanged Notes, as the case may be, with such reduction and/or offset subject to a cap.

The cap price of the capped call transactions will initially be $123.20 per share, which represents a premium of 75.0% over the last reported sale price of PBF Energy's Common Stock of $70.40 per share on September 14, 2026, and is subject to certain adjustments under the terms of the capped call transactions.

The Issuers have been advised that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to enter into various derivative transactions with respect to PBF Energy's Common Stock and/or purchase shares of PBF Energy's Common Stock or other securities of PBF Energy in secondary market transactions concurrently with, or shortly after, the pricing of the Notes, including with, or from, as the case may be, certain investors in the Notes. This activity could increase (or reduce the size of any decrease in) the market price of PBF Energy's Common Stock or the Notes at that time. In addition, the Issuers and PBF Energy expect that the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to PBF Energy's Common Stock and/or purchasing or selling PBF Energy's Common Stock or other securities of PBF Energy or the Issuers in secondary market transactions following the pricing of the Notes and prior to the maturity of the Notes (and are likely to do so (x) during any observation period related to an exchange of Notes, following any redemption of Notes by the Issuers or following any repurchase of Notes by the Issuers in connection with any fundamental change and (y) following any repurchase of the Notes by the Issuers other than in connection with any such redemption or any fundamental change if the Issuers elect to unwind a corresponding portion of the capped call transactions in connection with such repurchase). This activity could also cause or avoid an increase or a decrease in the market price of PBF Energy's Common Stock or the Notes, which could affect the ability of holders to exchange the Notes, and, to the extent the activity occurs during any observation period related to an exchange of Notes, it could affect the number of shares of PBF Energy's Common Stock, if any, and value of the consideration that holders will receive upon exchange of the Notes.

The Issuers estimate that the net proceeds from the offering will be approximately $485.0 million (or approximately $533.6 million if the initial purchasers fully exercise their option to purchase additional Notes), after deducting the initial purchasers' discounts and commissions and the Issuers' estimated offering expenses. The Issuers intend to use $25.2 million of the net proceeds from the offering to pay the cost of the capped call transactions, and the remainder, together with available cash, to fund the repayment or redemption, as applicable, of all of its outstanding 7.875% Senior Unsecured Notes due 2030 (the "2030 Notes"). If the initial purchasers exercise their option to purchase additional Notes, the Issuers expect to use a portion of the proceeds from the sale of the additional Notes to enter into additional capped call transactions with the option counterparties, and for general corporate purposes. Pending such use, the Issuers may repay other debt and/or invest the net proceeds in short-term, interest-bearing deposit accounts.

The offer and sale of the Notes, the related guarantees and any shares of PBF Energy's Common Stock deliverable upon exchange of the Notes have not been registered under the Securities Act or any other securities laws, and the Notes, such guarantees and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. The Notes and the related guarantees will only be offered and sold to persons who are reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the Securities Act). This press release does not constitute a notice of repayment or notice of redemption of the 2030 Notes.